IS7016A - Ný 4-anilínókínólín-3-karboxamíð - Google Patents

Ný 4-anilínókínólín-3-karboxamíð

Info

Publication number
IS7016A
IS7016A IS7016A IS7016A IS7016A IS 7016 A IS7016 A IS 7016A IS 7016 A IS7016 A IS 7016A IS 7016 A IS7016 A IS 7016A IS 7016 A IS7016 A IS 7016A
Authority
IS
Iceland
Prior art keywords
anilinoquinoline
carboxamide
new
Prior art date
Application number
IS7016A
Other languages
English (en)
Inventor
Larsson Joakim
Sjö Peter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7016A publication Critical patent/IS7016A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS7016A 2001-05-11 2003-11-05 Ný 4-anilínókínólín-3-karboxamíð IS7016A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101675A SE0101675D0 (sv) 2001-05-11 2001-05-11 Novel composition
PCT/SE2002/000875 WO2002092571A1 (en) 2001-05-11 2002-05-06 Novel 4-anilinoquinoline-3-carboxamides

Publications (1)

Publication Number Publication Date
IS7016A true IS7016A (is) 2003-11-05

Family

ID=20284085

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7016A IS7016A (is) 2001-05-11 2003-11-05 Ný 4-anilínókínólín-3-karboxamíð

Country Status (25)

Country Link
US (2) US7037925B2 (is)
EP (1) EP1387830A1 (is)
JP (1) JP2004533452A (is)
KR (1) KR20040007547A (is)
CN (1) CN1286815C (is)
AR (1) AR037489A1 (is)
BG (1) BG108325A (is)
BR (1) BR0209431A (is)
CA (1) CA2446717A1 (is)
CZ (1) CZ20033034A3 (is)
EE (1) EE200300544A (is)
HU (1) HUP0401339A2 (is)
IL (1) IL158517A0 (is)
IS (1) IS7016A (is)
MX (1) MXPA03010207A (is)
MY (1) MY134136A (is)
NO (1) NO20034992D0 (is)
NZ (1) NZ529302A (is)
PL (1) PL366766A1 (is)
RU (1) RU2281940C2 (is)
SE (1) SE0101675D0 (is)
SK (1) SK13712003A3 (is)
UA (1) UA76142C2 (is)
WO (1) WO2002092571A1 (is)
ZA (1) ZA200308350B (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
MXPA06000675A (es) 2003-07-24 2006-04-19 Astellas Pharma Inc Derivado de quinolona o sal del mismo.
SI2392564T1 (sl) 2003-09-26 2014-02-28 Exelixis, Inc. c-Met modulatorji in postopki uporabe
GB0322722D0 (en) * 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
EP1711495A2 (en) 2004-01-23 2006-10-18 Amgen Inc. Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
RU2415678C2 (ru) * 2004-05-03 2011-04-10 Новартис Аг Комбинации, включающие агонист рецептора s1p и ингибитор киназы jak3
CA2581516C (en) 2004-10-12 2013-06-11 Astrazeneca Ab Quinazoline derivatives
RU2391338C2 (ru) 2004-10-19 2010-06-10 Ф.Хоффманн-Ля Рош Аг Производные хинолина
TW200800963A (en) 2005-10-28 2008-01-01 Astrazeneca Ab Chemical compounds
JP2009528336A (ja) * 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キノリン誘導体
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
ES2427247T3 (es) 2006-03-13 2013-10-30 Kyorin Pharmaceutical Co., Ltd. Aminoquinolonas como inhibidores de GSK-3
PL2010496T3 (pl) * 2006-04-14 2011-01-31 Astrazeneca Ab 4-Anilinochinolino-3-karboksyamidy jako inhibitory kinazy CSF-1R
WO2007139496A1 (en) * 2006-05-30 2007-12-06 Clanotech Ab Quinoline derivatives acting as tyrosine kinase inhibitors
TW200829555A (en) * 2006-11-10 2008-07-16 Astrazeneca Ab Chemical compounds
CL2008000191A1 (es) * 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
EP2203458B1 (en) * 2007-09-11 2011-11-02 Kyorin Pharmaceutical Co., Ltd. Cyanoaminoquinolones as gsk-3 inhibitors
CN101855229A (zh) 2007-09-12 2010-10-06 埃迪威克斯生物科学公司 作为gsk-3抑制剂的螺环状氨基喹诺酮
PT2323993E (pt) 2008-04-16 2015-10-12 Portola Pharm Inc 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US20110190272A1 (en) * 2008-05-07 2011-08-04 Astrazeneca Ab Chemical compounds
JPWO2010058846A1 (ja) * 2008-11-21 2012-04-19 アステラス製薬株式会社 ４，６−ジアミノニコチンアミド化合物
MX2011007620A (es) 2009-01-16 2011-11-04 Exelixis Inc Sal de malato de n(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n '-(4-fluorofenil) ciclopropano-1,1-dicarboxamida, y sus formas cristalinas para el tratamiento de cancer.
BRPI1008974A2 (pt) 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
TW201040162A (en) 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2806332C (en) 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
UY33549A (es) * 2010-08-10 2012-01-31 Glaxo Group Ltd Quinolil aminas como agentes inhibidores de las quinasas
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
ES2609578T3 (es) 2011-03-04 2017-04-21 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
US9359308B2 (en) 2011-11-23 2016-06-07 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
AU2014219024B2 (en) 2013-02-20 2018-04-05 KALA BIO, Inc. Therapeutic compounds and uses thereof
AR094707A1 (es) 2013-02-21 2015-08-19 Glaxosmithkline Ip Dev Ltd Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
WO2016125187A1 (en) * 2015-02-03 2016-08-11 Council Of Scientific & Industrial Research Novel quinoline derivatives and preparation thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10723701B2 (en) 2016-10-18 2020-07-28 Beijing Konruns Pharmaceutical Co., Ltd. Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037925A (en) * 1958-04-09 1962-06-05 Smith Corp A O Cathodically protected structure and method of making same
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
IL141434A0 (en) 1998-08-21 2002-03-10 Parker Hughes Inst Quinazoline derivatives

Also Published As

Publication number Publication date
UA76142C2 (en) 2006-07-17
SE0101675D0 (sv) 2001-05-11
US20040248923A1 (en) 2004-12-09
US20060173034A1 (en) 2006-08-03
CN1507434A (zh) 2004-06-23
PL366766A1 (en) 2005-02-07
MY134136A (en) 2007-11-30
EE200300544A (et) 2004-02-16
IL158517A0 (en) 2004-05-12
KR20040007547A (ko) 2004-01-24
WO2002092571A1 (en) 2002-11-21
ZA200308350B (en) 2005-01-27
BR0209431A (pt) 2004-08-03
SK13712003A3 (en) 2004-10-05
HUP0401339A2 (hu) 2004-12-28
CN1286815C (zh) 2006-11-29
JP2004533452A (ja) 2004-11-04
US7037925B2 (en) 2006-05-02
HU0401339D0 (en) 2004-08-30
MXPA03010207A (es) 2004-03-10
BG108325A (bg) 2004-11-30
EP1387830A1 (en) 2004-02-11
AR037489A1 (es) 2004-11-17
NZ529302A (en) 2004-08-27
CA2446717A1 (en) 2002-11-21
RU2281940C2 (ru) 2006-08-20
RU2003131679A (ru) 2005-05-10
NO20034992D0 (no) 2003-11-10
CZ20033034A3 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
IS7016A (is) Ný 4-anilínókínólín-3-karboxamíð
DE50204184D1 (de) Espressobrüheinrichtung
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE60208051D1 (de) 3-substituierte-4-pyrimidonderivate
DE50103741D1 (de) Welle-Nabe-Verbindung
DE50208022D1 (de) Wischblatt
DE50204386D1 (de) Kreuztransducer
DE50212173D1 (de) sgängern
DE50206021D1 (de) Schlauchklemme
DE50209238D1 (de) Kugelgelenk
ATE335486T1 (de) Hydrazono-malonitrile
DE50204551D1 (de) Kugelgelenk
DE50211604D1 (de) Chlag
DE50209410D1 (de) Kugelgelenk
DE50208372D1 (de) Schrankaufhängevorrichtung
DE50211290D1 (de) Handzange
DE50204794D1 (de) Kugelgelenk
DE50203412D1 (de) Schwenkkolbenverdränger
DE50203984D1 (de) Kugelgelenk
DE50208029D1 (de) Kugelgelenk
ATE355059T1 (de) Isoxazolopyridinone
DE50201862D1 (de) Messwandler
DE50203093D1 (de) Losradlager
ATA18372001A (de) Gelenksbolzenbaueinheit
ATE319694T1 (de) Phenylalkyne